Blood Res 2017; 52(2): 143-145  https://doi.org/10.5045/br.2017.52.2.143
The imbalance of procoagulant and anticoagulant factors in patients with chronic liver diseases in North India
Priyanka Saxena1, Chhagan Bihari2, Roshni Mirza3, Ajeet Singh Bhadoria4, and Shiv K Sarin5

1Department of Pathology, Maulana Azad Medical College, New Delhi, India.

2Department of Pathology, Institute of Liver and Biliary Sciences, New Delhi, India.

3Department of Hematology, Institute of Liver and Biliary Sciences, New Delhi, India.

4Department of Clinical Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India.

5Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

Correspondence to: Priyanka Saxena. Department of Pathology, Maulana Azad Medical College, 1349, D-1, Vasant Kunj, New Delhi, India. docpriya06@rediffmail.com
Received: August 2, 2016; Revised: September 23, 2016; Accepted: November 18, 2016; Published online: June 22, 2017.
© The Korean Journal of Hematology. All rights reserved.

Body

TO THE EDITOR: Patients with chronic liver diseases (CLD) tend to experience severe hemostatic anomalies because of reduced levels of most of the coagulant proteins and anticoagulant factors such as protein C, protein S, and antithrombin. In contrast, it has been observed that levels of certain procoagulant factors such as factor VIII and von Willebrand factor (vWF) levels may be increased [1]. Various mechanisms such as increased levels of vWF antigen and reduced synthesis of ADAMTS 13 cleavage protease have been described to explain elevated factor VIII levels in these patients [2]. Additionally, the fact that factor VIII is an acute-phase reactant could elucidate partly these findings [3]. Not only increased procoagulant factor levels but a reduction in these factors may also lead to prothrombotic tendency in these patients. Concurrent reduction in protein C and factor VIII may also result in the procoagulant imbalance. It is important to distinguish the mechanism for increased factor VIII level in CLD patients since its sustained elevations may provoke the thrombosis. This study was aimed to compare the levels of factor VIII and protein C in CLD patients with a superimposed acute insult [acute-on-chronic liver failure (ACLF)] and in patients with compensated cirrhosis (CC), and to detect the correlations between the these factors and the disease activity using Model for End-Stage Liver Disease (MELD) scores in these respective groups. Furthermore, the ratio of factor VIII and protein C levels was evaluated as an indicator of the severity of liver disease in both groups.

This prospective study comprising 2 groups of patients with underlying CLD in a tertiary care center in North India was approved by the institutional Review board, with written informed consent obtained from all participants. Group 1 included 58 patients with ACLF (Asian Pacific Association for the Study of the Liver criteria [4]), and group 2 included 58 patients with biopsy-proven CC. The blood samples for coagulation study were collected from both groups using vacutainers containing buffered sodium citrate (0.109 M, 3.2%). The samples were processed within 30 minutes of collection. The citrated tubes were centrifuged at 3,000 g for 10 minutes to obtain plasma and analyzed for factor VIII and protein C on a fully automated coagulometer. The factor VIII and protein C values between the 2 groups were compared using the Mann-Whitney test and those of each group were analyzed the correlation with their MELD scores using Pearson's correlation. P-values of <0.05 were considered as statistically significant.

Patient characteristics are summarized in Table 1. The mean age in group 1 was 44.46±11.3 years with 89.7% being men, while in group 2, the mean age was 50.32±10.45 years with 94.8% being men. The median [interquartile range (IQR)] factor VIII and protein C levels in group 1 were 232.55% (150.0–331.5%) and 10.5% (10.25–22.10%), respectively, with a mean MELD score of 26.06±8.19. In group 2, the median (IQR) factor VIII and protein C levels were 178.20% (105.60–261.45%) and 36.8% (25.3–45.07%), respectively, with a mean MELD score of 16.19±3.91. The differences in factor VIII (P=0.04) and protein C (P<0.001) levels between the 2 groups were statistically significant.

The factor VIII levels in group 2 showed significantly positive correlation with MELD score, while those in group 1 did not show the significant correlation with their MELD score. A weak and negative correlation of protein C with MELD scores was seen in both groups, but it did not reach statistical significance. In addition to the above parameters, the ratio of factor VIII to protein C levels was calculated as an index of the procoagulant tendency in both groups. A statistically significant difference in the ratios between the 2 groups (P<0.001) was observed. The factor VIII to protein C ratio in group 1 showed a weak positive correlation with the MELD scores that was statistically insignificant, while the ratio in group 2 showed a weak positive but significant (P<0.001) correlation with MELD scores (Table 2).

Patients with CLD do not experience only bleeding complications but also thrombotic events. The main procoagulant drivers in CLD include elevated factor VIII and vWF and reduced protein C levels. Factor VIII elevations can arise from increased vWF levels, decreased expression of low-density lipoprotein receptor, and an acute-phase response to inflammation [2]. Of the 2 study groups included in our study, the ACLF group had patients with increased levels of C-reactive protein (44.0±29.3 mg/L) and procalcitonin (mean >2.10 ng/mL). However, the CC group had patients with no elevations of C-reactive protein (3±0.5 mg/L) and procalcitonin (mean <0.05 ng/mL). The factor VIII levels in both groups were elevated, but the elevation was significantly higher in the ACLF group, which can be attributed to additional acute insults. High factor VIII levels are a major risk factor in venous thrombosis [5] and may lead to thrombosis in CLD, especially in ACLF. Treatment of the acute-phase response in these patients might reduce the thrombotic tendencies.

Protein C levels are known to decrease in CLD as the liver is the major site of protein C synthesis. Our study has shown a significantly decrease in protein C levels in patients with ACLF (compared with the patients with CC), which may lead to an exacerbation of thrombotic tendencies in these patients. A negative correlation of protein C with the MELD score was observed in both groups, although the values were not statistically significant (Table 2).

Based on the fact that factor VIII is one of the most important components of thrombin generation and protein C is one of its most important inhibitors [6], the ratio of the 2 components was considered as an indicator of prothrombotic tendency. We found values in patients with CC similar to those of Tripodi et al. [7], but patients with ACLF had significantly higher ratios (Table 2). The ratio in the patients with CC had a direct and significant correlation with the MELD score compared to the ACLF group in which the coagulopathic defects were more serious. In patients with ACLF, other causes of hemostatic defects except for CLD, making more complex and heterogeneous coagulopathies, might interrupt correlation with MELD scores compared to those with CC [48].

To conclude, the patients with ACLF have higher factor VIII and lower protein C than those with CC. The factor VIII levels and the ratio of factor VIII to protein C may be used as a predictable marker for the severity of liver disease in patients with CC.

Tables
Table 1

Demographic and clinical characteristics of patients.

Abbreviations: F8, factor VIII; IQR, interquartile range; PrC, protein C; MELD, model for end-stage liver disease.


Table 2

Correlations coefficients with MELD score for each parameters.

Abbreviation: MELD, model for end-stage liver disease.


References
  1. Lisman, T, Caldwell, SH, Burroughs, AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol, 2010;53;362-371.
    Pubmed
  2. Hollestelle, MJ, Geertzen, HG, Straatsburg, IH, van Gulik, TM, van Mourik, JA. Factor VIII expression in liver disease. Thromb Haemost, 2004;91;267-275.
    Pubmed
  3. Noe, DA, Murphy, PA, Bell, WR, Siegel, JN. Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits. Am J Physiol, 1989;257;R49-R56.
    Pubmed
  4. Sarin, SK, Kumar, A, Almeida, JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int, 2009;3;269-282.
    Pubmed
  5. Kamphuisen, PW, Eikenboom, JC, Bertina, RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol, 2001;21;731-738.
    Pubmed
  6. Dahlbäck, B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol, 2004;79;109-116.
    Pubmed
  7. Tripodi, A, Primignani, M, Lemma, L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology, 2010;52;249-255.
    Pubmed
  8. Agarwal, B, Wright, G, Gatt, A, et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol, 2012;57;780-786.
    Pubmed


Current Issue

ba_link01

Indexed/Covered by

Today : 97  /
Total : 28,654